Clovis Oncology Inc. (NASDAQ:CLVS) has been given an average rating of “Hold” by the thirteen research firms that are currently covering the company. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $37.60.

Several brokerages have recently commented on CLVS. Vetr lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $35.23 price objective on the stock. in a research report on Wednesday, November 9th. Chardan Capital began coverage on Clovis Oncology in a research report on Tuesday, October 25th. They set a “sell” rating and a $15.00 price target on the stock. Stifel Nicolaus restated a “buy” rating and set a $45.00 price target on shares of Clovis Oncology in a research report on Monday, October 17th. Piper Jaffray Cos. restated a “neutral” rating and set a $42.00 price target on shares of Clovis Oncology in a research report on Wednesday, October 12th. Finally, Credit Suisse Group AG restated an “outperform” rating and set a $41.00 price target on shares of Clovis Oncology in a research report on Monday, October 10th.

Shares of Clovis Oncology (NASDAQ:CLVS) opened at 36.31 on Thursday. The company’s market cap is $1.40 billion. The stock’s 50 day moving average price is $32.29 and its 200 day moving average price is $22.26. Clovis Oncology has a 12-month low of $11.57 and a 12-month high of $40.29.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.95) by $0.25. During the same period in the prior year, the business earned ($2.62) EPS. On average, analysts forecast that Clovis Oncology will post ($8.97) EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLVS. Quantbot Technologies LP purchased a new position in Clovis Oncology during the third quarter worth approximately $103,000. BlackRock Inc. boosted its position in Clovis Oncology by 12.4% in the third quarter. BlackRock Inc. now owns 2,875 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 318 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in Clovis Oncology during the second quarter worth approximately $144,000. Fox Run Management L.L.C. purchased a new position in Clovis Oncology during the second quarter worth approximately $154,000. Finally, DIAM Co. Ltd. purchased a new position in Clovis Oncology during the third quarter worth approximately $168,000.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.